















- the reasons for worse outcomes. *thelancet.com/diabetes-endocrinology*, 8: 782 – 92.
- [29] Pugliese G., Vitale M., Resi V., and Orsi E., 2020, Is diabetes mellitus a risk factor for Coronavirus Disease 19 (COVID-19)? *Acta Diabetol.*, 31: 1 – 11. doi: 10.1007/s00592-020-01586-6.
- [30] Casqueiro J., Casqueiro J., and Alves C., 2012, Infections in patients with diabetes mellitus: A review of pathogenesis, *Indian Journal of Endocrinology and Metabolism*, 16 (1): 27 – 36. DOI: 10.4103/2230-8210.94253.
- [31] Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., *et al.*, 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases*, 94: 91–95. <https://doi.org/10.1016/j.ijid.2020.03.017>.
- [32] Guan W., Ni Z., Hu Y., Liang W., Ou C., He J. *et al.*, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China, *n engl j med*, 382: 1708 – 1720, DOI: 10.1056/NEJMoa2002032.
- [33] Pal R., and Bhadada S.K., 2020, COVID-19 and non-communicable diseases, *Postgrad Med J*, 96: 429 – 430.
- [34] Verma N., Duseja A., and Singh V., 2020, *Impact of Pre-existing Chronic Liver Disease on the Outcome of Patients with COVID-19 Disease*, *Gastroenterology* 2020, doi: <https://doi.org/10.1053/j.gastro.2020.05.090>. Date of access: 15/10/2020. [https://www.gastrojournal.org/article/S0016-5085\(20\)34782-X/pdf](https://www.gastrojournal.org/article/S0016-5085(20)34782-X/pdf).
- [35] Oyelade T., Alqahtani j., and Canciani G., 2020, Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis, *Trop. Med. Infect. Dis.*, 5 (80): 1 – 14. doi:10.3390/tropicalmed5020080.
- [36] Bonita R., Beaglehole R., and Kjellström T., 2006, *Basic epidemiology* 2<sup>nd</sup> edition. World Health Organization 2006. Date of access: 16/10/2020. [https://apps.who.int/iris/bitstream/handle/10665/43541/9241547073\\_eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/43541/9241547073_eng.pdf?sequence=1&isAllowed=y).
- [37] Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., *et al.*, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.*, 34(28): 2159-219. DOI: 10.1093/eurheartj/ehz151.
- [38] Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V., *et al.*, 2019, 2019 European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the European Association of the Study of Diabetes (EASD). *European Heart Journal*, 00: 1 – 69. DOI:10.1093/eurheartj/ehz486.
- [39] World Health Organization, 2009, *A Training Manual for Health Workers on Healthy Lifestyle: An Approach for the Prevention and Control of Non-Communicable Diseases*. Date of access: 1/10/2020. <http://www.wpro.who.int/philippines/publications/trainersguide.pdf>.
- [40] Kelly J., & Shull J., 2019, *Foundations of Lifestyle Medicine: The Lifestyle Medicine Board Review Manual*. 2<sup>nd</sup> ed. (Chesterfield, MO: United States of America).
- [41] United Nations, 2011, *Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases*. United Nations 2011, Date of access: 15/10/2020. [https://www.who.int/nmh/events/un\\_ncd\\_summit2011/political\\_declaration\\_en.pdf?ua=1](https://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf?ua=1).
- [42] Hunter C.L., Rubin H., and Kim K., 2020, *COVID-19 Economic Impacts: Beware the Ides of March – A Day Romans Settled Debts*, KPMG Economics 2020, Date of access: 15/10/2020. <https://assets.kpmg/content/dam/kpmg/cl/pdf/2020-03-kpmg-chile-advisory-coronavirus-mapping.pdf>.
- [43] Alschuler L, Weil A, Horwitz R, Stamets P., Chiassona A., Crockera R., and Maizesa V., 2020, Integrative considerations during the COVID-19 pandemic, *Explore*, (00):1 – 3.
- [44] World Health Organization, 2007, *Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk*. Date of access: 8/10/2020. [http://www.who.int/cardiovascular\\_diseases/guidelines/Full%20text.pdf](http://www.who.int/cardiovascular_diseases/guidelines/Full%20text.pdf).
- [45] Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein J. H., *et al.*, 2008, Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation, *J. Am. Coll. Cardiol.*, 51, 1512 – 1524. DOI: 10.1016/j.jacc.2008.02.034.
- [46] University of Leicester, 2012, Updated. *The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management*. Date of access: 31/12/2016. [https://legacyscreening.phe.org.uk/policydb\\_download.php?doc=259](https://legacyscreening.phe.org.uk/policydb_download.php?doc=259).